Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Unigene and Nordic Bioscience enter license agreement for metabolic peptide analogues

May 13, 2013

Orgenesis and ATMI enter into process development agreement for diabetes

May 13, 2013

Phase II results reported for ETC-1002 in patients with diabetes and dyslipidemia

May 13, 2013

Abbott obtains CE Mark for diabetes diagnostic

May 10, 2013

Nimbus Discovery and Shire to codevelop treatments for lysosomal storage disorders

May 10, 2013

Flexible dosing of insulin degludec achieves glycemic control

May 10, 2013

Drug for asthma may have clinical application to treat obesity

May 9, 2013

Agile Therapeutics presents phase III results for Twirla, a novel contraceptive patch

May 8, 2013

Aileron Therapeutics completes first trial of a stapled peptide

May 8, 2013

Osphena now available in U.S. pharmacies

May 7, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...